<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02886715</url>
  </required_header>
  <id_info>
    <org_study_id>0454-01-01</org_study_id>
    <secondary_id>0454</secondary_id>
    <nct_id>NCT02886715</nct_id>
  </id_info>
  <brief_title>A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fougera Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fougera Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing
      Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a
      Vehicle Control in the Treatment of Acne Vulgaris
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2016</start_date>
  <completion_date type="Actual">May 31, 2017</completion_date>
  <primary_completion_date type="Actual">May 31, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Inflammatory Lesion Counts</measure>
    <time_frame>Week 12</time_frame>
    <description>Percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Non-inflammatory Lesion Counts</measure>
    <time_frame>Week 12</time_frame>
    <description>Percent change from baseline to week 12 in the non-inflammatory (open and closed comedones) lesion counts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response of Success</measure>
    <time_frame>Week 12</time_frame>
    <description>The proportion of subjects with a clinical response of success at week 12, success defined as an Investigator's Global Assessment score that is at least two grades less than the baseline assessment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1110</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazarotene Cream 0.1%</intervention_name>
    <description>Tazarotene Cream 0.1% applied to cover the affected areas of the face once daily for 84 +/- 4 days.</description>
    <arm_group_label>Test</arm_group_label>
    <other_name>Tazarotene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazorac®</intervention_name>
    <description>Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.</description>
    <arm_group_label>Reference</arm_group_label>
    <other_name>Tazarotene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or non-pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis
             of acne vulgaris.

          -  Must have a minimum of ≥ 25 non-inflammatory lesions and ≥ 20 inflammatory lesions and
             ≤ 2 nodulocystic lesions at baseline on the face.

          -  Must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as
             per the Investigator's Global Assessment.

        Exclusion Criteria:

          -  Female subjects who are pregnant, nursing or planning to become pregnant during study
             participation.

          -  Have a history of hypersensitivity or allergy to tazarotene, retinoids and/or any of
             the study medication ingredients.

          -  Presence of any skin condition that would interfere with the diagnosis or assessment
             of acne vulgaris.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela C. Kaplan</last_name>
    <role>Study Director</role>
    <affiliation>Fougera Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Conway</city>
        <state>Arkansas</state>
        <zip>72034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <zip>94582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <zip>91790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Sweetwater</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <zip>18201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Upper Saint Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <results_first_submitted>May 31, 2018</results_first_submitted>
  <results_first_submitted_qc>July 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2018</results_first_posted>
  <last_update_submitted>July 19, 2018</last_update_submitted>
  <last_update_submitted_qc>July 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Tazarotene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02886715/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02886715/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>At Baseline Visit eligible subjects were randomized to the Test, Reference or Placebo product in a 2:2:1 ratio using an interactive response technology (IRT) system</recruitment_details>
      <pre_assignment_details>1154 subjects were screened for study participation, 1110 subjects were randomized and included in the statistical analyses.
25 investigative sites randomized subjects into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Test</title>
          <description>Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)</description>
        </group>
        <group group_id="P2">
          <title>Reference</title>
          <description>TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="442"/>
                <participants group_id="P2" count="445"/>
                <participants group_id="P3" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified ITT (mITT)</title>
              <participants_list>
                <participants group_id="P1" count="421"/>
                <participants group_id="P2" count="418"/>
                <participants group_id="P3" count="217"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol (PP) Population</title>
              <participants_list>
                <participants group_id="P1" count="346"/>
                <participants group_id="P2" count="351"/>
                <participants group_id="P3" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="378"/>
                <participants group_id="P2" count="390"/>
                <participants group_id="P3" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non-Compliance With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>missing</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test</title>
          <description>Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)</description>
        </group>
        <group group_id="B2">
          <title>Reference</title>
          <description>TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="442"/>
            <count group_id="B2" value="445"/>
            <count group_id="B3" value="223"/>
            <count group_id="B4" value="1110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Started (Safety Population)</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.5" spread="7.0"/>
                    <measurement group_id="B2" value="22.7" spread="7.0"/>
                    <measurement group_id="B3" value="22.5" spread="7.0"/>
                    <measurement group_id="B4" value="22.6" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Started (Safety Population)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="547"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Started (Safety Population)</population>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                    <measurement group_id="B2" value="252"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Inflammatory Lesion Counts</title>
        <description>Percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts</description>
        <time_frame>Week 12</time_frame>
        <population>mITT for superiority versus placebo, PP for equivalence versus Reference</population>
        <group_list>
          <group group_id="O1">
            <title>Test</title>
            <description>Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)</description>
          </group>
          <group group_id="O2">
            <title>Reference</title>
            <description>TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Lesion Counts</title>
          <description>Percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts</description>
          <population>mITT for superiority versus placebo, PP for equivalence versus Reference</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="418"/>
                <count group_id="O3" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58.44" spread="1.33"/>
                    <measurement group_id="O2" value="-60.07" spread="1.32"/>
                    <measurement group_id="O3" value="-53.28" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>90% Confidence Interval for the least-squares mean Test/Reference ratios to be within 80-125%</non_inferiority_desc>
            <param_type>Test-to-Reference Ratio</param_type>
            <param_value>98.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.39</ci_lower_limit>
            <ci_upper_limit>103.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0185</p_value>
            <method>ANOVA</method>
            <method_desc>with treatment and site as fixed effects in the model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.46</ci_lower_limit>
            <ci_upper_limit>-0.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response of Success</title>
        <description>The proportion of subjects with a clinical response of success at week 12, success defined as an Investigator's Global Assessment score that is at least two grades less than the baseline assessment</description>
        <time_frame>Week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Test</title>
            <description>Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)</description>
          </group>
          <group group_id="O2">
            <title>Reference</title>
            <description>TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response of Success</title>
          <description>The proportion of subjects with a clinical response of success at week 12, success defined as an Investigator's Global Assessment score that is at least two grades less than the baseline assessment</description>
          <population>mITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="418"/>
                <count group_id="O3" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="23.7"/>
                    <measurement group_id="O3" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Non-inflammatory Lesion Counts</title>
        <description>Percent change from baseline to week 12 in the non-inflammatory (open and closed comedones) lesion counts</description>
        <time_frame>Week 12</time_frame>
        <population>mITT for superiority versus placebo, PP for equivalence versus Reference</population>
        <group_list>
          <group group_id="O1">
            <title>Test</title>
            <description>Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)</description>
          </group>
          <group group_id="O2">
            <title>Reference</title>
            <description>TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Non-inflammatory Lesion Counts</title>
          <description>Percent change from baseline to week 12 in the non-inflammatory (open and closed comedones) lesion counts</description>
          <population>mITT for superiority versus placebo, PP for equivalence versus Reference</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="418"/>
                <count group_id="O3" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.11" spread="1.27"/>
                    <measurement group_id="O2" value="-51.99" spread="1.26"/>
                    <measurement group_id="O3" value="-45.72" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>90% Confidence Interval for the least-squares mean Test/Reference ratios to be within 80-125%</non_inferiority_desc>
            <param_type>Test-to-Reference Ratio</param_type>
            <param_value>98.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.42</ci_lower_limit>
            <ci_upper_limit>103.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0354</p_value>
            <method>ANOVA</method>
            <method_desc>with treatment and site as fixed effects in the model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.48</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to week 12 (end of study)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test</title>
          <description>Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)</description>
        </group>
        <group group_id="E2">
          <title>Reference</title>
          <description>TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="442"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="442"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Application site exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="442"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="442"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="442"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="442"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="442"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="442"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Fougera' agreements with its investigators may vary. However, Fougera does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela C Kaplan</name_or_title>
      <organization>Fougera Pharmaceuticals Inc.</organization>
      <phone>631-659-2256</phone>
      <email>angela.kaplan@sandoz.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

